Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Grass allergen extracts are standardized biologic preparations derived from the pollens of grasses such as timothy (*Phleum pratense*) and other related species. They are used as immunotherapy to treat allergic rhinitis with or without conjunctivitis caused by sensitivity to grass pollens. These extracts work by gradually desensitizing the immune system to specific allergens through repeated sublingual administration, thereby reducing symptoms like sneezing, runny nose, itchy eyes, and congestion during pollen season. The mechanism of action is based on modulating the immune response to reduce hypersensitivity reactions upon exposure to natural allergens[1][2][3][4][5][8]. Grass allergen extracts do not provide immediate symptom relief but can induce long-term tolerance when taken regularly before and during allergy seasons[4]. Major products include Grastek (timothy grass), Oralair (mixed grasses), and Grazax (timothy grass)[1][2][3][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Grass allergen extract.